Design Therapeutics, Inc.

What they do

Design Therapeutics develops GeneTAC gene targeted chimera small molecules designed to modulate gene expression in diseases caused by nucleotide repeat expansions. Its lead candidate, DT-216P2, is in a Phase 1/2 trial (RESTORE-FA) for Friedreich ataxia; DT-818 is in a Phase 1 MAD trial for myotonic dystrophy type-1; DT-168 is in a Phase 2 biomarker trial for Fuchs endothelial corneal dystrophy; and a Huntington's disease program is in preclinical development. The company has no approved products and no product revenue.

Revenue drivers

• No product revenue — The company has generated no revenue from product sales; annual revenue was $0.00 in both 2024 and 2025, and quarterly revenue was $0.00 in the quarters ended March 31, 2025 and March 31, 2026.
• Pre-commercial pipeline — All value is derived from the potential of its GeneTAC platform, with the most advanced asset being DT-216P2 for Friedreich ataxia, followed by DT-818 and DT-168 in earlier stages.

Recent performance

For the second quarter of 2026, the company reported a net loss of $20.2 million, with R&D expenses of $16.4 million and G&A expenses of $5.8 million. As of June 30, 2026, cash, cash equivalents and investment securities were $207.4 million, while total assets were $215.1 million and shareholder equity was $201.9 million. For the full year 2025, net loss was $69.8 million and diluted EPS was -$1.22; operating cash flow was -$54.4 million. In May 2026, the company announced positive four-week data from the RESTORE-FA trial, showing dose-dependent increases in frataxin and improvements in clinical measures.

Strategy

The company is prioritizing DT-216P2 for Friedreich ataxia, modifying the RESTORE-FA trial to evaluate 1 mpk as the go-forward dose and to explore a dose above 1 mpk, with plans to define registrational pathway in Q4 2026. It is also advancing DT-818 for DM1, with dosing initiated in a Phase 1 MAD trial, and DT-168 for FECD, though data is delayed to 2027 due to supply issues with blow-fill-seal eye droppers. The broader strategy leverages the GeneTAC platform across multiple repeat expansion diseases, including Huntington's disease, with ongoing preclinical work and discovery efforts.

Risks

• Clinical and regulatory risk — DT-216P2 received a clinical hold from the FDA in June 2025, which was lifted in December 2025, but future holds or trial delays remain possible.
• Dependence on early-stage data — The company's most advanced candidate has only four-week clinical data; durability and efficacy over 12 weeks are unproven.
• Supply chain risk — The DT-168 FECD trial data is delayed to 2027 due to a delay in the supply of the DT-168 blow-fill-seal eye droppers, highlighting manufacturing vulnerabilities.
• No revenue and ongoing losses — The company has no product revenue and has incurred net losses every year since at least 2021, with a net loss of $69.8 million in 2025.

Outlook

Management expects to provide an update on registrational plans for DT-216P2 in the fourth quarter of 2026, with data from 12 weeks of dosing expected in the first quarter of 2027. The company anticipates reporting data from the DT-818 DM1 trial in 2027 and expects DT-168 FECD data in 2027. Cash and securities of $207.4 million at quarter-end provide a financial runway, though no specific runway length was stated.